Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.0B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for serious diseases. With a market cap of $6 billion, it operates in the Health Care sector, which is increasingly important as innovative treatments and personalized medicine gain traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted slightly negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has consistently missed EPS estimates in recent quarters. Investors are cautious, given the lack of management guidance.

Bull Case

If Cogent can show improved cost management and a clearer path to revenue growth, it may regain investor confidence and drive the stock higher.

Bear Case

Continued misses on earnings and revenue could lead to further declines in stock price, especially if the market perceives a lack of progress in its drug development pipeline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any delays or advancements, as this will impact future revenue potential and investor sentiment.

How does management plan to improve EPS moving forward?

Given the recent trend of missing EPS estimates, any concrete plans for improvement will be critical for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly focused on past EPS misses without considering potential improvements in drug development timelines and cost management strategies.

Supporting Evidence

Options are pricing a 10.4% move, indicating expectations of volatility that may not align with historical performance.

The company has a history of positive stock reactions despite EPS misses, suggesting that the market may be underestimating future potential.

Key Risk

If the company can demonstrate a clear path to reducing EPS losses, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Cogent can demonstrate progress in its financial performance and drug development.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would indicate improved cost management and operational efficiency.

Bear Confirmed If

If EPS remains above -$0.70, it would signal ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive turnaround.

In-Line / Cautious

An in-line report may lead to muted reactions, as the market will likely focus on management commentary regarding future guidance.

Miss

If the company misses again, history suggests a potential decline of around +3.44%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of drug candidates in the pipeline.
2Management's strategy for improving EPS and reducing losses.
3Insights into revenue growth expectations for the upcoming quarters.
4Comments on market conditions and competitive landscape.
5Any new partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

Congress activity

RecapView

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3-2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted slightly negatively the following day, indicating investor disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has consistently missed EPS estimates in recent quarters. Investors are cautious, given the lack of management guidance.

Bull Case

If Cogent can show improved cost management and a clearer path to revenue growth, it may regain investor confidence and drive the stock higher.

Bear Case

Continued misses on earnings and revenue could lead to further declines in stock price, especially if the market perceives a lack of progress in its drug development pipeline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any delays or advancements, as this will impact future revenue potential and investor sentiment.

How does management plan to improve EPS moving forward?

Given the recent trend of missing EPS estimates, any concrete plans for improvement will be critical for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly focused on past EPS misses without considering potential improvements in drug development timelines and cost management strategies.

Supporting Evidence

Options are pricing a 10.4% move, indicating expectations of volatility that may not align with historical performance.

The company has a history of positive stock reactions despite EPS misses, suggesting that the market may be underestimating future potential.

Key Risk

If the company can demonstrate a clear path to reducing EPS losses, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Cogent can demonstrate progress in its financial performance and drug development.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would indicate improved cost management and operational efficiency.

Bear Confirmed If

If EPS remains above -$0.70, it would signal ongoing challenges in achieving profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive turnaround.

In-Line / Cautious

An in-line report may lead to muted reactions, as the market will likely focus on management commentary regarding future guidance.

Miss

If the company misses again, history suggests a potential decline of around +3.44%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of drug candidates in the pipeline.
2Management's strategy for improving EPS and reducing losses.
3Insights into revenue growth expectations for the upcoming quarters.
4Comments on market conditions and competitive landscape.
5Any new partnerships or collaborations that could enhance growth prospects.